Larvol Delta - Coya-Therapeutics-Coya-Announces-Completion-of-Enrollment-in-a-WellControlled-Phase-2-Study-of-Low-Dose-Interleukin2-LD-IL2-in-Patients-with-Alzheimers-Disease-AD

COYA 301 - Coya Therap

https://www.businesswire.com/news/home/20231009522751/en/Coya-Therapeutics-Coya-Announces-Completion-of-Enrollment-in-a-Well-Controlled-Phase-2-Study-of-Low-Dose-Interleukin-2-LD-IL-2-in-Patients-with-Alzheimer%E2%80%99s-Disease-AD

Oct 9, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next